Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Biphenotypic Acute Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Burkitt Lymphoma
- Chronic Myelogenous Leukemia
- Relapsed Small Lymphocytic Lymphoma
- Hodgkin Lymphoma
- Lymphoplasmacytic Lymphoma
- Relapsed Marginal B-cell Lymphoma
- Mantle Cell Lymphoma
- Relapsed Follicular Lymphoma
- Myelodysplastic Syndromes
- Relapsed Chronic Lymphocytic Leukemia
- Undifferentiated Leukemia
- Myeloproliferative Neoplasm
- Relapsed Large Cell Lymphoma
- Relapsed T-Cell Lymphoma
- Prolymphocytic Leukemia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04191187
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Hany Elmariah, MD, MS Moffitt Cancer Center Principal Investigator: Nelli Bejanyan, MD Moffitt Cancer Center
Get Well Soon